Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Galapagos, a drug discovery company, and Dart Neuroscience, a developer of new therapies to help maintain cognitive vitality, have signed new collaboration agreements in drug discovery and compound management. Total potential value of the contracts for Galapagos is E4.1 million over three years.
Subscribe to our email newsletter
Pursuant to the terms of the collaboration, Galapagos’s service division, BioFocus DPI, will develop a cell-based assay for Dart Neuroscience’s (DNS’s) drug discovery programs for brain disorders and perform high-throughput screening and hit expansion using BioFocus DPI’s compound collections. Furthermore, BioFocus DPI will carry out compound management for DNS over the next three years.
Onno van de Stolpe, CEO of Galapagos, said: “This collaboration maximizes several key BioFocus DPI strengths – assay development and high-throughput screening as well as compound libraries and compound management.
“We are particularly pleased that our compound management facility in San Francisco continues to help us win new contracts and clients – we have seen strong progress in development of this business in 2008.”
Tim Tully, chief scientific officer of DNS, said: “We are confident that BioFocus DPI’s integrated offering will contribute to advancing our drug discovery programs focused on various aspects of cognitive dysfunction.”